Literature DB >> 11476898

Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

M Fridkis-Hareli1, J N Stern, L Fugger, J L Strominger.   

Abstract

Copolymer 1 (Cop 1, poly [Y, E, A, K]) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB1*1501). In the present study various peptides, synthesized according to the binding motifs for both the immunodominant epitope of myelin basic protein (MBP) 85-99, a candidate autoantigen in MS, and Cop 1, differentially inhibited binding of these antigens to disease-associated HLA-DR2 (DRB1*1501) molecules. In particular, two peptides with residue K at position P-1, as referred to MBP 85-99, inhibited effectively the binding of both biotinylated MBP 85-99 and Cop 1 to HLA-DR2 molecules as well as IL-2 production by two MBP-specific HLA-DR2-restricted T-cell clones. These findings suggest the possible utility of these compounds or their more stable derivatives in treatment of MS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476898     DOI: 10.1016/s0198-8859(01)00279-8

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Masha Fridkis-Hareli; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

2.  Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

Authors:  Cassandra E Smith; Todd N Eagar; Jack L Strominger; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

3.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

4.  Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

Authors:  Masha Fridkis-Hareli; Laura Santambrogio; Joel N H Stern; Lars Fugger; Celia Brosnan; Jack L Strominger
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  A Modified Peptide Derived from Goodpasture Autoantigen Arrested and Attenuated Kidney Injuries in a Rat Model of Anti-GBM Glomerulonephritis.

Authors:  Yue Shi; Xiao-Yu Jia; Qiu-Hua Gu; Miao Wang; Zhao Cui; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2019-10-30       Impact factor: 10.121

Review 6.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

7.  Regulation of EAE by spontaneously generated IL-10-secreting regulatory T cells in HLA-DR15/TCR.Ob1A12 double transgenic mice.

Authors:  Ester Leno-Durán; Sze-Ling Ng; Jack L Strominger
Journal:  Immunology       Date:  2021-03-22       Impact factor: 7.215

8.  Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

Authors:  Vilena V Ivanova; Svetlana F Khaiboullina; Marina O Gomzikova; Ekaterina V Martynova; André M Ferreira; Ekaterina E Garanina; Damir I Sakhapov; Yakov A Lomakin; Timur I Khaibullin; Evgenii V Granatov; Farit A Khabirov; Albert A Rizvanov; Alexander Gabibov; Alexey Belogurov
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 9.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.